摘要
BACKGROUND: Glucocorticoid has been used extensively in clinical applications, because of its several pharmacologic actions, which include immunosuppression, anti-inflammation, anti-shock, and relief of asthma. However, the long-term or high-dose application of glucocorticoid can induce adverse effects such as osteoporosis, which is known in this case as glucocorticoid-induced osteoporosis (GIOP). It is a secondary osteoporosis that results in easy fracturing, and even disability. Therefore it became a thorny issue. METHODS: The rat model of glucocorticoid-induced osteoporosis (GIOP) was replicated to isolate BMSCs. Rats were assigned into four groups: normal, normal induction, GIOP, and GIOP induction. The growth cycle was monitored by using flow cytometry. Osteogenic differentiation was compared by using alkaline phosphatase (ALP) staining with a modified calcium cobalt method. The quantitative detection of osteoprotegerin and the receptor activator of nuclear factor kappa-B ligand (RANKL) was conducted by using enzyme-linked immunoassay. Finally, renal Klotho mRNA expression was assessed by using RT-PCR. RESULTS: BMSC proliferation was reduced in GIOP rats. The ALP-positive expression of normal BMSCs to the osteogenic induction solution was stronger than that of BMSCs from GIOP rats (P < 0.01). Osteoprotegerin expression was significantly higher in the normal induction group than in the normal, GIOP (P < 0.01), and GIOP induction groups (P < 0.05). RANKL expression was significantly higher in the normal induction group than in the other groups (P < 0.01) and significantly higher in the normal group than in the GIOP and GIOP induction groups (P < 0.01). RT-PCR analysis showed that renal Klotho mRNA expression was significantly reduced in the GIOP group compared with the normal group (P < 0.01). CONCLUSION: BMSC proliferation, osteogenic differentiation, and reactive activity to an osteogenic inductor were reduced in GIOP rats. Klotho mRNA expression decreased during GIOP induction.
- A Core Omnigenic Non-coding Trait Governing Dex-Induced Osteoporotic Effects Identified Without DEXALu, Li; Cai, Yanzhen; Luo, Xiaoling; Wang, Zhangting; Fung, Sin Hang; Jia, Huanhuan; Yu, Chi Lam; Chan, Wai Yee; Miu, Kai Kei*; Xiao, Wende*Frontiers in Pharmacology, 2021, 12: 750959.
- 从Wnt/β-catenin和OPG/RANKL/RANK信号通路探讨糖皮质激素诱发骨质疏松症的可能途径魏秋实; 邓伟民; 陈现红; 黄伟毅; 谭新; 孙伟珊; 邵玉; 潘志国中国骨质疏松杂志, 2013, (06): 626-630.
- Treatment options for glucocorticoid-induced osteoporosisIacopo Chiodini; Daniela Merlotti; Alberto Falchetti; Luigi GennariEXPERT OPINION ON PHARMACOTHERAPY, 2020, 21(6): 721-732.
